Humacyte Inc
NASDAQ:HUMA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
M
|
Myungmoon Pharm Co Ltd
KRX:017180
|
KR |
|
I
|
Iktinos Hellas Greek Marble Industry SA
ATHEX:IKTIN
|
GR |
|
Wing Fung Group Asia Ltd
HKEX:8526
|
HK |
|
D
|
DeFi Technologies Inc
NEO:DEFI
|
CA |
|
C
|
Clean Logistics SE
XETRA:SD1
|
DE |
|
Everi Holdings Inc
NYSE:EVRI
|
US |
|
P
|
Petron Malaysia Refining & Marketing Bhd
KLSE:PETRONM
|
MY |
|
C
|
China Shineway Pharmaceutical Group Ltd
HKEX:2877
|
CN |
|
S
|
SNTEnergy Co Ltd
KRX:100840
|
KR |
Humacyte Inc
Operating Expenses
Humacyte Inc
Operating Expenses Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Humacyte Inc
NASDAQ:HUMA
|
Operating Expenses
-$100.5m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Operating Expenses
-$22.9B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-9%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Operating Expenses
-$11.4B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-6%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Operating Expenses
-$14.1B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-5%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Operating Expenses
-$5.7B
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-15%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Operating Expenses
-$8.5B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-13%
|
|
Humacyte Inc
Glance View
Humacyte, Inc. engages in the manufacture of human acellular matrix products for vascular and non-vascular applications. The company is headquartered in Durham, North Carolina and currently employs 145 full-time employees. The company went IPO on 2020-09-22. The company is developing a portfolio of human acellular vessels (HAVs) with varying diameters and lengths. The HAV cabinet would initially target the vascular repair, reconstruction and replacement market, including vascular trauma; atrioventricular (AV) access for hemodialysis; peripheral arterial disease (PAD); and coronary artery bypass grafting (CABG). The firm has developed a paradigm for manufacturing human tissues that is intended to mimic key aspects of human physiology. The company is developing and manufacturing acellular tissues to address life- and limb-threatening vascular conditions while focusing on potential future applications for complex tissue and organ diseases. The company is also engaged in developing its HAVs for pediatric heart surgery and the delivery of cellular therapies, including pancreatic islet cell transplantation to treat Type 1 diabetes.
See Also
What is Humacyte Inc's Operating Expenses?
Operating Expenses
-100.5m
USD
Based on the financial report for Dec 31, 2025, Humacyte Inc's Operating Expenses amounts to -100.5m USD.
What is Humacyte Inc's Operating Expenses growth rate?
Operating Expenses CAGR 5Y
-9%
Over the last year, the Operating Expenses growth was 12%. The average annual Operating Expenses growth rates for Humacyte Inc have been -5% over the past three years , -9% over the past five years .
